Antibiotic discovery: where have we come from, where do we go?
| Autor: | Cecília R.C. Calado, Bernardo Ribeiro da Cunha, Luís P. Fonseca |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Streptogramins Proteomics medicine.medical_specialty medicine.drug_class Antibiotic discovery platforms Polymyxin 030106 microbiology Antibiotics Review Drug resistance Fully synthetic antibiotics semi-synthesis Biochemistry Microbiology fully synthetic antibiotics Macrolide Antibiotics 03 medical and health sciences proteomics genomics Medicine Metabolomics Pharmacology (medical) drug screening General Pharmacology Toxicology and Pharmaceutics Intensive care medicine metagenomics business.industry Semi-synthesis lcsh:RM1-950 Genomics metabolomics lcsh:Therapeutics. Pharmacology 030104 developmental biology Infectious Diseases Drug screening Lipidomics lipidomics antibiotic discovery platforms Metagenomics business Amphenicols Beta lactam antibiotics |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP Antibiotics, Vol 8, Iss 2, p 45 (2019) Antibiotics |
| Popis: | Given the increase in antibiotic-resistant bacteria, alongside the alarmingly low rate of newly approved antibiotics for clinical usage, we are on the verge of not having effective treatments for many common infectious diseases. Historically, antibiotic discovery has been crucial in outpacing resistance and success is closely related to systematic procedures—platforms—that have catalyzed the antibiotic golden age, namely the Waksman platform, followed by the platforms of semi-synthesis and fully synthetic antibiotics. Said platforms resulted in the major antibiotic classes: aminoglycosides, amphenicols, ansamycins, beta-lactams, lipopeptides, diaminopyrimidines, fosfomycins, imidazoles, macrolides, oxazolidinones, streptogramins, polymyxins, sulphonamides, glycopeptides, quinolones and tetracyclines. During the genomics era came the target-based platform, mostly considered a failure due to limitations in translating drugs to the clinic. Therefore, cell-based platforms were re-instituted, and are still of the utmost importance in the fight against infectious diseases. Although the antibiotic pipeline is still lackluster, especially of new classes and novel mechanisms of action, in the post-genomic era, there is an increasingly large set of information available on microbial metabolism. The translation of such knowledge into novel platforms will hopefully result in the discovery of new and better therapeutics, which can sway the war on infectious diseases back in our favor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|